StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Atrium Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-27.8%+306.9
Q2 FY2026Jun 30, 2026-672.0%−198.4
Q1 FY2026Mar 31, 2026-84.7%–
Q3 FY2025Sep 30, 2025-0.3%–
Q2 FY2025Jun 30, 2025-334.8%–
Q1 FY2025Mar 31, 2025-473.6%–

More Atrium Therapeutics figures

See a number that looks wrong?